Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the month of March 2022. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It solely reports specific share transaction details:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Price: $41.1900 per ADS.
- Transaction Date: February 24, 2022.
- Exchange: New York Stock Exchange (XNYS).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of ADSs by executives via dividend reinvestment plans.
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a regulatory disclosure of the following specific transactions:
- Dr. H. Barron (Chief Scientific Officer and President, R&D): Acquired 90 ADSs via the GSK 401(k) plan and 3,282.633 notional ADSs via the Executive Supplemental Savings Plan.
- Mr. J. Ford (SVP and Group General Counsel): Acquired 75.736 notional ADSs via the Executive Supplemental Savings Plan.
All transactions were acquisitions resulting from the reinvestment of dividends.
Key Facts for Investor Verification
- Verify the total number of ADSs held by Dr. Barron and Mr. Ford post-transaction to assess overall insider ownership levels.
- Confirm that the transaction price of $41.1900 aligns with the market price of GSK ADSs on February 24, 2022.
- Note that these transactions were automatic dividend reinvestments, not discretionary open-market purchases.